Scholarlink

<p>Head and neck squamous cell carcinomas (HNSCC) are a group of frequently occurring tumors with a high rate of relapse and 5-year survival of approximately 60%. Novel diagnostic and prognostic biomarkers analyzed in liquid biopsy could improve clinical management of patients and prolong their survival. Thus, the aim of this study was to evaluate the utility of DNA methylation analysis in the clinical management of HNSCC patients. Based on our previous studies and the analysis of TCGA data, we selected six epigenetically regulated genes, which differentiated HNSCC patients from healthy controls. Next, we used a two-step nested MethyLight assay to analyze the DNA methylation of <i>DAPK1</i>,<i> LHX2</i>,<i> MGMT</i>,<i> RAPGEFL1</i>,<i> RARB</i>, and <i>RYR2</i> in HNSCC tumor samples, which was followed by confirmatory analysis of cfDNA from plasma samples in another cohort of HNSCC patients. We provided evidence for the relevance of <i>DAPK1</i>,<i> LHX2</i>,<i> MGMT</i>,<i> RAPGEFL1</i>,<i> RARB</i>, and <i>RYR2</i> methylation analysis in HNSCC diagnosis. Importantly, the methylation of <i>RAPGEFL1</i>,<i> RARB</i>, and <i>RYR2</i> in tumor samples was found to be associated with HNSCC recurrence. The presence of methylation of <i>RARB</i> and <i>LHX2</i> in cfDNA distinguished HNSCC patients from healthy controls. Overall, we report that <i>LHX2</i>, <i>RAPGEFL1</i>,<i> RARB</i>, and <i>RYR2</i> are promising candidates for a methylation-based diagnostic tool in HNSCC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The methylation of LHX2, RAPGEFL1, RARB and RYR2 has prognostic significance in head and neck squamous cell carcinoma patients

  • 期刊论文

  • 发表日期：

    2026年3月2日

查看全文
  • Marcin Skalski,
  • Ewelina Kowal-Wiśniewska,
  • Katarzyna Jaskiewicz-Rajewicz,
  • Katarzyna Kiwerska,
  • Anna Bartochowska,
  • Adam Ustaszewski,
  • Tomasz Górecki,
  • Aleksandra Majchrzak-Celińska,
  • Małgorzata Wierzbicka,
  • Małgorzata Jarmuż-Szymczak,
  • Jarosław Paluszczak

摘要

Head and neck squamous cell carcinomas (HNSCC) are a group of frequently occurring tumors with a high rate of relapse and 5-year survival of approximately 60%. Novel diagnostic and prognostic biomarkers analyzed in liquid biopsy could improve clinical management of patients and prolong their survival. Thus, the aim of this study was to evaluate the utility of DNA methylation analysis in the clinical management of HNSCC patients. Based on our previous studies and the analysis of TCGA data, we selected six epigenetically regulated genes, which differentiated HNSCC patients from healthy controls. Next, we used a two-step nested MethyLight assay to analyze the DNA methylation of DAPK1, LHX2, MGMT, RAPGEFL1, RARB, and RYR2 in HNSCC tumor samples, which was followed by confirmatory analysis of cfDNA from plasma samples in another cohort of HNSCC patients. We provided evidence for the relevance of DAPK1, LHX2, MGMT, RAPGEFL1, RARB, and RYR2 methylation analysis in HNSCC diagnosis. Importantly, the methylation of RAPGEFL1, RARB, and RYR2 in tumor samples was found to be associated with HNSCC recurrence. The presence of methylation of RARB and LHX2 in cfDNA distinguished HNSCC patients from healthy controls. Overall, we report that LHX2, RAPGEFL1, RARB, and RYR2 are promising candidates for a methylation-based diagnostic tool in HNSCC patients.